EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC-ND 4.0

Glucosuria as a Marker of Adherence to Sodium-Glucose Cotransporter 2 Inhibitors and Clinical Outcomes in Real-World Practice

Zongpu Li iD, Aditya Surapaneni iD, David M Charytan iD, Leora I Horwitz iD, Saul Blecker iD, Jung-Im Shin iD, Lorna E Thorpe iD, Michal L Melamed iD, Morgan E Grams iD

Journal of the American Society of Nephrology · 17.09.2026

DOI: 10.1681/asn.0000001252 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of the American Society of Nephrology, online erschienen am 17.09.2026. Verfasst von Zongpu Li und 8 weiteren Autor:innen. Beteiligte Einrichtung: Vilcek Institute of Graduate Biomedical Sciences, New York University Grossman School of Medicine, New York, New York. Die Arbeit nennt 24 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: NIDDK NIH HHS, NHLBI NIH HHS, National Institute of Diabetes and Digestive and Kidney Diseases.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Key Points Glucosuria is a proxy for adherence to sodium-glucose cotransporter 2 (SGLT2) inhibitors. Patients with glucosuria during SGLT2 inhibitor prescriptions have lower risk of mortality, heart failure, and kidney failure.

Background

Medication nonadherence contributes to the efficacy–effectiveness gap in real-world practice. Glucosuria, routinely measured on urinalysis, may serve as an objective proxy for assessing medication adherence to sodium-glucose cotransporter 2 (SGLT2) inhibitors, a class of medications that reduce the risks of kidney disease, heart failure, and mortality.

Methods

We leveraged 2 cohorts from the Optum Labs Data Warehouse real-world data (2014–2023): cohort 1 included 3987 patients with SGLT2 inhibitor pharmacy claims and a urinalysis performed both before and during active fill periods; cohort 2 included 45,711 patients prescribed SGLT2 inhibitors with urinalysis performed within 6 months after initiation. Glucosuria was defined as urine glucose 2+ or greater. Cohort 2 was followed for a mean of 3.3 years for all-cause mortality, heart failure hospitalization, and kidney failure; fractures were used as a negative control outcome.

Results

In cohort 1, SGLT2 inhibitor use (versus no use) was associated with 18.1-fold higher odds of glucosuria (95% confidence interval [CI], 16.4 to 20.0), adjusted for diabetes status. In cohort 2, 26,657 (58%) had glucosuria within 6 months of SGLT2 inhibitor initiation, suggesting adherence. After inverse probability of treatment weighting, glucosuria was associated with lower risks of all-cause mortality (hazard ratio [HR], 0.78; 95% CI, 0.73 to 0.83), heart failure hospitalization (HR, 0.87; 95% CI, 0.78 to 0.98), and kidney failure (HR, 0.73; 95% CI, 0.58 to 0.91) compared with no glucosuria. No association was observed with fractures (HR, 1.00; 95% CI, 0.95 to 1.06).

Conclusions

Glucosuria was associated with SGLT2 inhibitor adherence and, among patients prescribed SGLT2 inhibitors, is associated with reductions in risks of all-cause mortality, heart failure, and kidney failure.

Schlagwörter

Stichwörter der Autor:innen

CKDSGLT2 inhibitorscardiovascular eventsheart failure

Autor:innen und Institutionen

  • Vilcek Institute of Graduate Biomedical Sciences, New York University Grossman School of Medicine, New York, New York.
  • Division of Precision Medicine, Department of Medicine, New York University Grossman School of Medicine, New York, New York.
  • Division of Nephrology, Department of Medicine, New York University Grossman School of Medicine, New York, New York.
  • Department of Population Health, New York University Grossman School of Medicine, New York, New York.
  • Department of Epidemiology, Johns Hopkins University Bloomberg School of Public Health, Baltimore, Maryland.

ORCID-Profile: Zongpu Li, Aditya Surapaneni, David M Charytan, Leora I Horwitz, Saul Blecker, Jung-Im Shin, Lorna E Thorpe, Michal L Melamed, Morgan E Grams

Förderung

  • NIDDK NIH HHS
  • NHLBI NIH HHS
  • National Institute of Diabetes and Digestive and Kidney Diseases
  • National Heart, Lung, and Blood Institute

Zitieren

APA

Li, Z., Surapaneni, A., Charytan, D. M., Horwitz, L. I., Blecker, S., Shin, J. I., Thorpe, L. E., Melamed, M. L., & Grams, M. E. (2026). Glucosuria as a Marker of Adherence to Sodium-Glucose Cotransporter 2 Inhibitors and Clinical Outcomes in Real-World Practice. Journal of the American Society of Nephrology. https://doi.org/10.1681/asn.0000001252

Vancouver

Li Z, Surapaneni A, Charytan DM, Horwitz LI, Blecker S, Shin JI, et al. Glucosuria as a Marker of Adherence to Sodium-Glucose Cotransporter 2 Inhibitors and Clinical Outcomes in Real-World Practice. Journal of the American Society of Nephrology. 2026. doi:10.1681/asn.0000001252

BibTeX
@article{Li2026,
  author = {Li, Zongpu and Surapaneni, Aditya and Charytan, David M and Horwitz, Leora I and Blecker, Saul and Shin, Jung-Im and Thorpe, Lorna E and Melamed, Michal L and Grams, Morgan E},
  title = {Glucosuria as a Marker of Adherence to Sodium-Glucose Cotransporter 2 Inhibitors and Clinical Outcomes in Real-World Practice},
  journal = {Journal of the American Society of Nephrology},
  year = {2026},
  doi = {10.1681/asn.0000001252}
}
Kostenlos starten →